AQST News and Press, Aquestive Therapeutics Inc. From 03/29/23

2023-03-29 09:15:13 ET Aquestive Therapeutics ( NASDAQ: AQST ) expanded its exclusive license and supply agreement with Atnahs Pharma UK (Pharmanovia) for seizure therapy Libervant (diazepam) Buccal Film. The expanded agreement will cover the rest of the world, e...

WARREN, N.J., March 29, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today announced it has expanded i...

2023-03-09 11:14:00 ET Aquestive Therapeutics ( NASDAQ: AQST ) ticked higher in the morning hours Thursday, shortly after Wedbush upgraded its shares to Outperform from Neutral, citing an extended cash runway following the company's Q4 2022 results. The analyst Andreas...

2023-03-08 11:45:22 ET Aquestive Therapeutics, Inc. (AQST) Q4 2022 Results Conference Call March 08, 2023 08:00 AM EST Company Participants Bennett Watson - Westwicke, Investor Relations Dan Barber - Chief Executive Officer Ernie Toth - Senior Vice President, Chi...

2023-03-07 16:05:49 ET Aquestive Therapeutics press release ( NASDAQ: AQST ): Q4 GAAP EPS of -$0.23 in-line. Revenue of $10.68M beats by $0.26M . 2023 Outlook Aquestive is providing its full year 2023 financial outlook. Total revenue (in millions) - $37...

Pivotal study for AQST-109 (epinephrine sublingual film) on track to start in third quarter 2023 Financial turnaround actions on track including 18% reduction of outstanding debt and the receipt of $20 million of non-dilutive capital in the first quarter of 2023 Continues to engage FDA on...

WARREN, N.J., March 01, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, announced today that the managem...

WARREN, N.J., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative produc...

WARREN, N.J., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative product...

Anticipates commencing pivotal pharmacokinetic (PK) trial for AQST-109 (epinephrine sublingual film) in second half of 2023 Anticipates receipt in the coming months of FDA response to request for Libervant ™ (diazepam) Buccal Film accelerated market access Expects preli...